We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial.
- Authors
Kim, Chae-Yong; Paek, Sun Ha; Nam, Do-hyun; Chang, Jong-Hee; Hong, Yong-Kil; Kim, Jeong Hoon; Kim, Oh Lyong; Kim, Se-Hyuk
- Abstract
Background: Tumor treating fields (TTFields) are anti-mitotic, non-invasive loco-regional cancer therapy comprising low intensity, intermediate frequency alternating electric fields. TTFields plus Temozolomide (TTFields/TMZ) extended survival versus TMZ alone in newly diagnosed glioblastoma (GBM) patients in the EF-14 trial. We report on Korean newly diagnosed GBM patients who participated in the EF-14 trial. Methods: Thirty-nine participants of the EF-14 trial were enrolled at 8 sites in South Korea. Patients (24 TTFields/TMZ; 14 TMZ alone) received: TTFields (200 kHz) for > 18 h/day; TMZ at 120–150 mg for 5 days per a 28 day cycle. Safety and efficacy were assessed. Results: Patient baseline characteristics were balanced in the 2 arms and the mean age was 52.1 years, 66.7% were male with a mean KPS of 90. Safety incidence was comparable between the 2 arms. In the TTFields/TMZ arm, 30% suffered from skin irritation versus 52% in the entire study population. No TTFields-related serious adverse events were reported. The median progression-free survival (PFS) in the TTFields/TMZ arm was 6.2 months (95% CI 4.2–12.2) versus 4.2 (95% CI 1.9–11.2) with TMZ alone (p = 0.67). Median overall survival was 27.2 months (95% CI 21-NA) with TTFields/TMZ versus 15.2 months (95% CI 7.5–24.1; HR 0.27, p = 0.01) with TMZ alone. Conclusion: Median OS and 1- and 2-year survival rates were higher with TTFields/TMZ and similar to the entire EF-14 population. About 30% of patients reported skin irritation, a lower rate than seen in the entire EF-14 population. These results demonstrate the efficacy and safety of TTFields in Korean newly diagnosed glioblastoma patients. Clinical Trials: Clinicaltrials.gov Identifier: NCT00916409.
- Subjects
SOUTH Korea; TEMOZOLOMIDE; PROGRESSION-free survival; GLIOBLASTOMA multiforme; IRRITATION (Pathology); CANCER treatment; ELECTRIC field therapy
- Publication
Journal of Neuro-Oncology, 2020, Vol 146, Issue 3, p399
- ISSN
0167-594X
- Publication type
Article
- DOI
10.1007/s11060-019-03361-2